Aarti Drugs Gets Relief as Bombay HC Halts ₹20.72 Cr Penalty

Introduction

The Bombay High Court has provided significant ad interim relief to Aarti Drugs Limited by directing Central Goods & Service Tax (CGST) authorities to halt any coercive action for the recovery of a substantial penalty. This decision comes as a respite for the pharmaceutical company, which has been contesting a large demand related to Integrated Goods and Services Tax (IGST) refunds.

The Core of the Dispute

The case originated from a Show Cause Notice (SCN) issued to Aarti Drugs for an alleged contravention of Rule 96(10) of the CGST Rules. The notice proposed a massive demand of ₹230.70 crores, including applicable interest and penalties, for the financial years 2017-18 to 2021-22. Following the proceedings, the CGST & Central Excise Authority passed an order confirming a demand for an erroneous IGST refund amounting to ₹20.72 crores under Section 74(9) of the CGST Act, 2017. The authority also imposed an equivalent penalty of ₹20.72 crores and demanded interest on the amount. However, a significant portion of the initial proposed demand, ₹209.98 crores, was dropped.

High Court's Intervention

In response to a writ petition filed by Aarti Drugs, a division bench of the Bombay High Court reviewed the matter. The court granted an ad interim stay on the recovery of the penalty, providing immediate relief to the company and preventing the tax authorities from taking coercive measures until the next hearing. This favorable court decision means there will be no immediate financial or operational impact on the company from this specific order, ensuring stability in its ongoing activities.

A Broader Trend of Tax Litigation

The situation faced by Aarti Drugs is not isolated. Several Indian corporations are currently engaged in high-stakes litigation with revenue departments. In a separate case, the Supreme Court recently declined to entertain a Special Leave Petition from the Income Tax Department against Reliance Industries Limited. The petition challenged a Bombay High Court judgment that had nullified assessment orders issued to two companies that had already merged with Reliance. The Supreme Court dismissed the plea, noting that the department had already issued a fresh notice to the correct entity, Reliance Industries, as per the High Court's directive.

Insurance Sector Faces Similar Challenges

The trend extends to the insurance sector as well. The Bombay High Court recently granted a temporary stay to over a dozen insurance companies, including Aditya Birla Health Insurance, Oriental Insurance, and SBI General Insurance, against GST demands and penalties exceeding ₹10,000 crore. The court's interim protection offers a meaningful safeguard for the industry, which has been grappling with these substantial legacy tax exposures. The matter will now be decided on its merits, but the stay prevents immediate financial strain on the companies.

Summary of Recent Tax Disputes

Revenue's Poor Success Rate in Appeals

Legal experts have noted a pattern where revenue departments frequently lose cases when they appeal High Court decisions to the Supreme Court. An analysis of a random selection of ten such cases revealed that the revenue department lost outright in seven, with the High Court's orders being only partially modified in the remaining three. This suggests that the High Court verdicts are often well-reasoned, and escalating every matter to the Supreme Court may not be a productive strategy for the tax authorities. This has led to calls for the Central Board of Indirect Taxes and Customs (CBIC) to consider accepting High Court verdicts in appropriate cases rather than pursuing further litigation.

Other Legal Hurdles for Aarti Drugs

Beyond the CGST matter, Aarti Drugs has faced other tax-related challenges. The Maharashtra Tax Department recently issued an order for the provisional attachment of the company's bank accounts over a claimed tax liability of ₹13.36 crore, with the total claim in the order reaching ₹213.36 crore including interest and penalty. The company has stated its intention to file an objection against this order. In a separate matter at the Delhi High Court, the company withdrew its challenge against a government memorandum concerning the imposition of Anti-Dumping Duty on Ofloxacin imports from China, leading to the case being disposed of as infructuous.

Conclusion

The interim relief granted to Aarti Drugs by the Bombay High Court underscores the critical role of the judiciary in scrutinizing large tax demands imposed by revenue authorities. This case, along with similar instances involving Reliance and major insurance firms, highlights a broader trend of corporations successfully challenging tax claims in higher courts. While tax departments continue to pursue significant demands, the courts are providing a crucial check, ensuring that actions are in accordance with the law. The outcomes of these ongoing legal battles will continue to shape the landscape of tax litigation in India.